Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Manchester, UK – 22 May 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the reappointment of Dr. Joanne Mason, Chief Scientific Officer, as a Director of the Company with immediate effect.
Dr. Mason has been leading the development of Yourgene’s next generation molecular diagnostics, in particular in the area of reproductive health, helping the Company deliver on its new product roadmap and commercial success. Given Dr Mason’s background and experience in this field, she is playing an increasingly pivotal role for the Company in highlighting the technical benefits of the Company’s offerings to potential and existing customers, and her expertise provides an important complement to the skills and understanding of the wider Board.
Disclosures in accordance with the AIM Rules
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Dr. Joanne Nicola Mason (aged 49):
|Current appointments||Former appointments in the past 5 years|
|Yourgene Health UK Ltd||Yourgene Health plc|
Dr. Mason holds 7,509,480 ordinary shares and 1,000,000 options over new ordinary shares in the Company.
There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Cairn Financial Advisers LLP (NOMAD)|
Liam Murray / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|Singer Capital Markets (Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Alice Woodings / Lianne Applegarth
Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 / Mob: 07407 804 654 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group’s portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.
Building on our expertise in genomic technology, Yourgene’s Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.
Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”.